Targets › PTEN
2 programs from 2 companies in 2 trials: 1 Phase 1, 1 Phase 3; Oncology, Metabolic and endocrine; next expected readout Dec 2026.
Dual-specificity protein phosphatase, dephosphorylating tyrosine-, serine- and threonine-phosphorylated proteins. Also functions as a lipid phosphatase, removing the phosphate in the D3 position of the inositol ring of PtdIns(3,4,5)P3/phosphatidylinositol 3,4,5-trisphosphate, PtdIns(3,4)P2/phosphatidylinositol 3,4-diphosphate and PtdIns3P/phosphatidylinositol 3-phosphate with a preference for PtdIns(3,4,5)P3. (UniProt, P60484)
Open in Phaseline: the race on PTEN, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Amgen | Pegloticase Recombinant uricase enzyme that catalyzes degradation of uric acid | PTEN | Phase 3 | Uncontrolled Gout | Jun 2028 |
| Pharosgen | MPD-1 Doxorubicin prodrug targeting KRAS mutant/PTEN loss advanced cancer | KRAS, PTEN | Phase 1 | Cancer | Dec 2026 |
Cancer (1) Uncontrolled Gout (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.